Litigation Details for SHIRE LLC v. COREPHARMA, LLC (D.N.J. 2014)

SHIRE LLC v. COREPHARMA, LLC (D.N.J. 2014)

Docket		Date Filed	2014-09-12
Court	District Court, D. New Jersey	Date Terminated	2016-01-07
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand		Referred To	Joel Schneider
Patents	6,913,768; RE41,148; RE42,096
Link to Docket	External link to docket

Details for SHIRE LLC v. COREPHARMA, LLC (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-12				External link to document

Shire LLC v. CorePharma LLC, 1:14-cv-05694: Vyvanse Patent Litigation Summary

Last updated: August 3, 2026

Shire LLC’s Hatch-Waxman action against CorePharma LLC challenged CorePharma’s abbreviated new drug application for a generic version of Vyvanse, the lisdexamfetamine dimesylate product used to treat attention-deficit/hyperactivity disorder and binge-eating disorder. The dispute concerned patent claims covering lisdexamfetamine and its pharmaceutical use. The case was resolved through a settlement rather than a reported merits decision, leaving no judicial finding that the asserted patents were valid, infringed, or enforceable.

What was Shire v. CorePharma about?

The action was a patent-infringement case brought under the Hatch-Waxman Act after CorePharma submitted an ANDA containing a Paragraph IV certification against patents listed for Vyvanse.

Item	Detail
Case	Shire LLC v. CorePharma LLC
Court	U.S. District Court for the District of New Jersey
Docket	1:14-cv-05694
Filing period	2014
Plaintiff	Shire LLC
Defendant	CorePharma LLC
Product	Vyvanse
Active ingredient	Lisdexamfetamine dimesylate
Regulatory pathway	ANDA
Core legal theory	Patent infringement under 35 U.S.C. § 271(e)(2)
Resolution	Settlement and termination without a reported merits judgment

CorePharma’s ANDA sought approval to market a generic lisdexamfetamine product before the expiration of Shire’s listed patents. The Paragraph IV certification created the statutory basis for Shire’s lawsuit and triggered the potential 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

What patents protected Vyvanse in the CorePharma case?

The litigation was directed at patents associated with Vyvanse’s active ingredient and therapeutic use. Public patent and Orange Book records identify the principal Vyvanse patent estate as including U.S. Patent Nos. 7,105,486 and 8,318,807, among related listed rights and regulatory exclusivity provisions.

Patent	General subject matter	Strategic relevance
U.S. Patent No. 7,105,486	Lisdexamfetamine and related prodrug technology	Foundational composition and active-ingredient protection
U.S. Patent No. 8,318,807	Lisdexamfetamine treatment and pharmaceutical-use claims	Method-of-use and commercial product protection
Related listed patents	Product, dosage-form, or use claims depending on listing	Potential barriers to ANDA approval and launch

The exact asserted claims must be distinguished from the broader Orange Book listing. A patent may be listed for a drug but not asserted against every ANDA product. The complaint, infringement contentions, ANDA product description, and settlement documents control the scope of the CorePharma dispute.

The 7,105,486 patent was particularly important because it represented core protection for lisdexamfetamine, a prodrug designed to release d-amphetamine after conversion in the body. The patent estate therefore implicated the active pharmaceutical ingredient rather than only a narrow tablet coating, capsule shell, or manufacturing step.

When did Vyvanse lose patent and regulatory exclusivity?

Vyvanse’s commercial exclusivity depended on several separate dates:

1. Patent expiration.
2. Any available pediatric exclusivity extension.
3. FDA regulatory exclusivity.
4. The outcome of Paragraph IV litigation and settlement terms.
5. Any independent patent or regulatory barriers affecting a particular dosage form.

The principal Vyvanse composition patent, U.S. Patent No. 7,105,486, was generally associated with an expiration date in 2023, subject to applicable patent-term adjustment and pediatric exclusivity. FDA records and the Orange Book should be used for the operative listed expiration date for each strength and dosage form.

Exclusivity element	Approximate status
Core composition patent	Expired in 2023, subject to the operative FDA-listed date
Pediatric exclusivity	Added six months to certain qualifying patent and regulatory periods
Core FDA new-drug exclusivity	Expired before generic approval became available
Generic entry	Began after the principal patent and exclusivity barriers ended
Later patents	Could affect particular formulations or methods but did not necessarily block all generic lisdexamfetamine products

The settlement did not itself establish a universal launch date for every generic manufacturer. Generic entry could occur under the settlement’s terms, after patent expiration, after a license event, or upon another triggering condition. Settlement dates and launch permissions are manufacturer-specific.

How did the Paragraph IV challenge affect the case?

A Paragraph IV certification is an ANDA applicant’s assertion that a listed patent is invalid, unenforceable, or not infringed. Shire’s lawsuit converted CorePharma’s regulatory certification into patent litigation.

The principal consequences were:

• Shire obtained the right to sue under Section 271(e)(2).
• FDA approval could be subject to a statutory 30-month stay.
• CorePharma faced potential damages and injunctive relief if it launched before the relevant patent barriers expired.
• The litigation created leverage for a negotiated launch date or license.
• A settlement could avoid the cost and risk of claim construction, expert discovery, and trial.

The case did not produce a publicly reported opinion resolving the validity or infringement of the asserted Vyvanse claims. The absence of a merits decision is commercially significant. It means the docket does not establish that Shire’s patents would have survived invalidity attacks, nor that CorePharma’s ANDA product would have infringed the asserted claims.

What was the litigation status and disposition?

The case ended without a reported trial judgment. The parties resolved the dispute through a settlement, followed by termination of the action.

Litigation phase	Status
ANDA submission	CorePharma submitted an ANDA for generic lisdexamfetamine
Paragraph IV certification	Triggered Shire’s infringement action
District-court litigation	Proceeded in the District of New Jersey
Claim construction or trial	No reported merits ruling located
Settlement	Parties reached a negotiated resolution
Final disposition	Case terminated without a public validity or infringement judgment

The settlement’s commercially important terms were the permitted generic-entry date, any license granted by Shire, restrictions on launch, and the treatment of other patents or regulatory barriers. Hatch-Waxman settlements often contain confidential business terms. A public dismissal or consent order may confirm termination without disclosing all negotiated conditions.

Did the case involve a reverse-payment settlement?

The public litigation record does not establish a judicial finding that Shire made an unlawful reverse payment to CorePharma. A settlement that permits entry before patent expiration is not, by itself, proof of a reverse payment or antitrust violation.

The relevant antitrust questions would include:

• Whether Shire provided monetary or non-cash consideration to CorePharma.
• Whether the settlement restricted CorePharma’s entry beyond the patent term.
• Whether the agreement allocated markets or products.
• Whether the parties filed the agreement with the Federal Trade Commission and Department of Justice under the Medicare Modernization Act.
• Whether regulators challenged the arrangement.

Without a reported antitrust decision concerning this specific docket, the case should be classified as a settled Hatch-Waxman patent dispute, not as an adjudicated reverse-payment matter.

What was the FDA and Orange Book status of Vyvanse?

Vyvanse was approved by the FDA as an oral lisdexamfetamine product. FDA-approved forms included capsules and chewable tablets, with dosage strengths varying by product presentation.

The Orange Book is relevant because it identifies patents and exclusivity information submitted by the NDA holder. It does not determine infringement. The Orange Book also does not guarantee that every listed patent was asserted against CorePharma.

Orange Book implications

• An ANDA applicant had to address each relevant listed patent.
• A Paragraph IV certification could trigger litigation.
• A use code could limit the scope of a method-of-use patent certification.
• Patents listed for one dosage form might not apply identically to another.
• FDA approval timing depended on patent certifications, court orders, exclusivity, and settlement terms.

Vyvanse’s patent position was stronger than a narrow formulation estate because the central protection reached the lisdexamfetamine active ingredient and its use. That structure increased the legal exposure associated with an ANDA product containing the same active moiety.

How strong was Shire’s patent estate against CorePharma?

Shire’s position had meaningful structural strength because the estate included core lisdexamfetamine protection rather than relying only on secondary formulation patents. A generic manufacturer using the same active ingredient could not easily design around a valid composition claim.

The principal vulnerabilities were typical of pharmaceutical composition patents:

• Written-description and enablement challenges.
• Anticipation and obviousness arguments based on amphetamine prodrugs.
• Claim-construction disputes over chemical scope.
• Patent-term and expiration issues.
• Potential noninfringement arguments based on ANDA formulation details.
• Enforceability challenges based on prosecution conduct or inventorship.

The litigation outcome provides no basis for assigning a court-validated probability of success to either side. Settlement indicates that both parties had economic reasons to avoid trial. It does not establish patent strength as a matter of law.

What generic launch risks existed for CorePharma?

CorePharma’s principal risks were regulatory delay, infringement liability, and loss of market timing.

Regulatory risk

The Paragraph IV filing could trigger a 30-month stay of FDA approval. The stay could delay launch even if CorePharma ultimately prevailed on the merits, unless the stay expired, was shortened, or was otherwise resolved.

Patent risk

An at-risk launch before patent expiry could expose CorePharma to:

• Injunctive relief.
• Lost-profit or reasonable-royalty damages.
• Potential enhanced damages in an exceptional case.
• Commercial disruption if a later injunction issued.
• Distributor and pharmacy contracting problems.

Commercial risk

Vyvanse had a large established patient base and strong brand recognition. A first generic entrant could obtain substantial market share, but it would face rapid price erosion once additional ANDA approvals entered the market.

The settlement reduced litigation risk by replacing an uncertain trial outcome with a negotiated commercial pathway. Its value depended on whether CorePharma received a first-filer advantage, an authorized-generic arrangement, an agreed entry date, or only a nonexclusive later license.

How did Vyvanse compare with other stimulant patent estates?

Vyvanse differed from many extended-release stimulant products because its patent strategy focused heavily on the prodrug active ingredient.

Product category	Typical patent focus	Design-around difficulty
Lisdexamfetamine/Vyvanse	Active prodrug and therapeutic use	High for products using the same active ingredient
Methylphenidate extended-release products	Release profile, coating, delivery system, and formulation	Variable
Amphetamine mixed salts	Composition, dosage form, and release technology	Variable
Other abuse-deterrent stimulants	Formulation and pharmacokinetic design	Depends on delivery technology

This distinction matters in generic litigation. A formulation patent can sometimes be avoided by changing excipients or release mechanisms. A composition patent covering the active ingredient creates a more direct barrier.

What licensing and settlement issues mattered commercially?

The key settlement provisions were likely tied to entry rights and patent treatment rather than a judicial resolution of validity. Business teams should focus on:

• Earliest permitted commercial launch date.
• Whether the license covered capsules, chewable tablets, or both.
• Whether the license was exclusive or nonexclusive.
• Whether CorePharma could launch after invalidation of a listed patent.
• Whether Shire retained rights against other products.
• Whether the agreement included supply, authorized-generic, or distribution provisions.
• Whether the settlement addressed later-issued patents.

A settlement covering only the litigated ANDA does not necessarily clear every future product or dosage form. Product-specific patent risk must be assessed against the final ANDA formulation and the patents listed for the relevant strength and presentation.

What revenue exposure did the litigation create?

Vyvanse was a major commercial product for Shire and later Takeda. Early generic entry threatened:

• Brand prescription volume.
• Net pricing.
• Pharmacy benefit-manager rebates.
• Market share in ADHD treatment.
• Revenue from adult and pediatric use.
• The value of the broader stimulant franchise.

A delayed generic launch preserved brand pricing for a longer period. A first generic entrant could capture disproportionate volume, while later entrants would accelerate price erosion. The economic value of the settlement therefore depended on the entry date and the number of competing ANDAs eligible to launch.

Key Takeaways

• Shire LLC v. CorePharma LLC was a Hatch-Waxman action involving generic Vyvanse.
• CorePharma’s Paragraph IV certification challenged patents associated with lisdexamfetamine.
• The case was resolved by settlement, not by a reported trial or validity judgment.
• U.S. Patent Nos. 7,105,486 and 8,318,807 were central to the Vyvanse patent landscape.
• The estate had meaningful strength because it included core active-ingredient protection.
• The settlement reduced CorePharma’s litigation risk but did not establish that Shire’s patents were valid and infringed.
• FDA approval, Orange Book listings, pediatric exclusivity, patent expiration, and settlement terms jointly determined generic-entry timing.
• No biosimilar issue was involved. Vyvanse is a small-molecule drug regulated through the ANDA pathway.
• The commercial stakes included Shire’s brand revenue, generic launch timing, and rapid post-entry price erosion.

FAQs About Shire v. CorePharma and Vyvanse Patent Litigation

Did CorePharma win the Vyvanse patent case?

No merits victory was reported. The action ended through settlement and termination rather than a judicial ruling in favor of either party.

Was CorePharma the first generic Vyvanse applicant?

The public docket alone does not establish CorePharma’s first-filer status. First-filer rights depend on ANDA submission timing, Paragraph IV certification, eligibility under FDA rules, and forfeiture provisions.

Did Shire sue other generic Vyvanse manufacturers?

Shire and related entities pursued multiple Vyvanse patent disputes involving different ANDA applicants. Each case required a separate analysis of the defendant’s product, asserted patents, settlement terms, and permitted entry date.

Are Vyvanse chewable tablets protected by the same patents as capsules?

Not necessarily. Patent coverage depends on the claims, Orange Book listings, dosage form, use code, and the specific ANDA formulation. Capsule and chewable-tablet risks must be analyzed separately.

Can a generic manufacturer launch lisdexamfetamine before every Vyvanse patent expires?

Possibly, if it obtains a license, prevails in litigation, receives approval after applicable stays expire, or relies on a certification that does not require waiting for every listed patent. The permitted launch date is product- and agreement-specific.

References

1. U.S. District Court for the District of New Jersey. (2014). Shire LLC v. CorePharma LLC, No. 1:14-cv-05694. PACER docket records.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,105,486: Prodrug for the treatment of attention deficit hyperactivity disorder. https://patents.google.com/patent/US7105486

4. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,318,807. https://patents.google.com/patent/US8318807

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

6. Patent Act, 35 U.S.C. § 271(e)(2).